Ob­sid­i­an Ther­a­peu­tics rakes in $160M for sol­id tu­mor cell ther­a­py pro­gram

Ob­sid­i­an Ther­a­peu­tics an­nounced Wednes­day that it raised $160.5 mil­lion to push its tu­mor-in­fil­trat­ing lym­pho­cyte (TIL) pro­gram fur­ther in clin­i­cal tri­als.

The Se­ries C raise comes af­ter Ob­sid­i­an re­port­ed ini­tial da­ta from six pa­tients with ad­vanced melanoma who re­ceived its tu­mor-in­fil­trat­ing lym­pho­cyte cell ther­a­py. With the new $160.5 mil­lion, Ob­sid­i­an plans to push its TIL ther­a­py, OBX-115, for­ward in mul­ti­cen­ter stud­ies in both melanoma and non-small cell lung can­cer.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER